Adjuvant treatment is treatment that is given after surgery to prevent the cancer from coming back.
During this video interview, suggested treatments for people whose cancer returns after adjuvant treatment with pembrolizumab is discussed.
The timing of the progression of the cancer is important. For example, if someone completes a year of pembrolizumab and has a disease recurrence after another couple of years, this patient could be treated with an immunotherapy combination.
But if progression happens while the patient is on adjuvant pembrolizumab, local treatment, such as stereotactic body radiotherapy (SBRT) or surgery could be used. This can be followed by a vascular endothelial growth factor (VEGF) inhibitor (e.g., sunitinib, pazopanib), especially if there are multiple new sites of spread, like liver metastases and bone metastases.